Jeffrey A. Lindeman, Ph.D., Esq.

Email: jeff.lindeman@jalindeman.com
Phone: 703-776-9705

Jeff Lindeman founded J.A. Lindeman & Co. PLLC on December 1, 2009. Jeff has a BA in chemistry from West Virginia University and a Ph.D. in chemistry from the University of South Carolina. His law degree is from the Georgetown University Law Center. Jeff has over 20 years of patent experience working with clients to prepare and prosecute patent applications in the U.S. and internationally. Jeff’s patent prosecution practice focuses on the chemical and pharmaceutical industries, with a particular area of emphasis in patenting crystalline forms of pharmaceuticals, e.g., polymorph and co-crystal patents.

An adjunct professor at American University’s Washington College of Law, Jeff has taught courses on patent prosecution, international patent law and US patent. He is a past chair of the Chemical Practice Committee for the American Intellectual Property Law Association and a former US patent examiner.

Jeff is a frequent speaker and has published articles on US patent law. Recent articles include the following:

  • Lindeman, J.A., PATENTING AMORPHOUS SOLID DISPERSIONS OF PHARMACEUTICALS, invited chapter, reviewed, revisions in draft.
  • Lindeman, J.A., Parisi, J. A., DRAFTING THE PATENT APPLICATION, invited ebook chapter, reviewed, revisions in draft.
  • Hoffman, M., Lindeman, J.A.; “CO-CRYSTALS: COMMERCIAL AND PATENT CONSIDERATIONS”, RSC Drug Discovery Series No. 16, Pharmaceutical Salts and Co-Crystals, Ch. 14, 2012.
  • Lindeman, J.A., “PATENTS AND THE US FDA’S DEFINITION OF ‘COCRYSTAL’: AN ORDINARY AND CUSTOMARY MEANING?,”Pharmaceutical Patent Analyst, November 2012, Vol. 1, No. 5, Pages 513-515.

In 2013, Jeff and the firm began working with the rare disease community. On December 12, 2013, Jeff presented a webinar for the National Organization of Rare Diseases, NORD, entitled “PATENTS AND RARE DISEASES – An Overview for Patient Advocacy Groups.”

Bar Admissions:  Virginia, District of Columbia, Tennessee.
Registered to practice before the U.S. Patent and Trademark Office.